Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis

Authors: Ming Meng, Huadan Xue, Jing Lei, Qin Wang, Jingjuan Liu, Yuan Li, Ting Sun, Haiyan Xu, Zhengyu Jin

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The aim of this study was to evaluate the early anti-tumor efficiency of different therapeutic agents with a combination of multi-b-value DWI, DCE-MRI and texture analysis.

Methods

Eighteen 4 T1 homograft tumor models were divided into control, paclitaxel monotherapy and paclitaxel and bevacizumab combination therapy groups (n = 6) that underwent multi-b-value DWI, DCE-MRI and texture analysis before and 15 days after treatment.

Results

After treatment, the tumors in the control group were significantly larger than those in the combination group (P = 0.018). In multi-b-value DWI, the ADCslow obviously increased in the combination group compared to that in the others (P < 0.01). The f increased in the control and paclitaxel groups, but the combination group showed a significant decrease versus the others (P < 0.02). Additionally, in DCE-MRI, the decreasing Ktrans showed an evident difference between the combination and control groups (P = 0.003) due to the latter’s increasing Ktrans. The intra-group comparisons of tumor texture in pre-, mid- and post-treatments showed that the entropy had all significantly increased in all groups (P < 0.01, SSF = 0–6), though the MPP, mean and SD increased only in the combination group (PMPP,mean,SD < 0.05, SSF = 4–6). Moreover, the inter-group comparisons revealed that the mean and MPP exhibited significant differences after treatment (Pmean,MPP < 0.05, SSF = 0–3).

Conclusion

All these results suggest some strong correlations among DWI, DCE and texture analysis, which are beneficial for further study and clinical research.
Literature
1.
go back to reference Fusco R, et al. Integration of DCE-MRI and DW-MRI quantitative parameters for breast lesion classification. BioMed. Res. Int. 2015;12:237863. Fusco R, et al. Integration of DCE-MRI and DW-MRI quantitative parameters for breast lesion classification. BioMed. Res. Int. 2015;12:237863.
2.
go back to reference Shin HJ, et al. Prediction of low-risk breast cancer using perfusion parameters and apparent diffusion coefficient. Magn Reson Imaging. 2016;34:67–74.CrossRefPubMed Shin HJ, et al. Prediction of low-risk breast cancer using perfusion parameters and apparent diffusion coefficient. Magn Reson Imaging. 2016;34:67–74.CrossRefPubMed
3.
go back to reference Brix G, Griebel J, Kiessling F, Wenz F. Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging. 2010;37(Suppl 1):S30–51.CrossRefPubMed Brix G, Griebel J, Kiessling F, Wenz F. Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging. 2010;37(Suppl 1):S30–51.CrossRefPubMed
4.
go back to reference Koo HR, et al. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers. J Magn Reson Imaging. 2012;36:145–51.CrossRefPubMed Koo HR, et al. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers. J Magn Reson Imaging. 2012;36:145–51.CrossRefPubMed
5.
go back to reference Anderson AW, et al. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging. 2000;18:689–95.CrossRefPubMed Anderson AW, et al. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging. 2000;18:689–95.CrossRefPubMed
6.
go back to reference Presta LG, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.PubMed Presta LG, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.PubMed
7.
go back to reference Horwitz SB. Mechanism of action of taxol. Trends Pharmacologicol Sci. 1992;13:134–6.CrossRef Horwitz SB. Mechanism of action of taxol. Trends Pharmacologicol Sci. 1992;13:134–6.CrossRef
8.
go back to reference Goh V, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165–71.CrossRefPubMed Goh V, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165–71.CrossRefPubMed
10.
go back to reference Ganeshan B, et al. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2013;266:326–36.CrossRefPubMed Ganeshan B, et al. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2013;266:326–36.CrossRefPubMed
11.
go back to reference Zhu W, Kato Y, Artemov D. Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. MAGMA. 2014;27:161–70.CrossRefPubMed Zhu W, Kato Y, Artemov D. Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. MAGMA. 2014;27:161–70.CrossRefPubMed
12.
go back to reference De Cecco CN, et al. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Investig Radiol. 2015;50:239–45.CrossRef De Cecco CN, et al. Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Investig Radiol. 2015;50:239–45.CrossRef
13.
go back to reference Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging. 2013;13:400–6.CrossRefPubMedPubMedCentral Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging. 2013;13:400–6.CrossRefPubMedPubMedCentral
14.
go back to reference Sieren JC, et al. Exploration of the volumetric composition of human lung cancer nodules in correlated histopathology and computed tomography. Lung Cancer. 2011;74:61–8.CrossRefPubMedPubMedCentral Sieren JC, et al. Exploration of the volumetric composition of human lung cancer nodules in correlated histopathology and computed tomography. Lung Cancer. 2011;74:61–8.CrossRefPubMedPubMedCentral
15.
go back to reference Rajkumar V. Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. Br J Cancer. 2015;112:1882–7.CrossRefPubMedPubMedCentral Rajkumar V. Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. Br J Cancer. 2015;112:1882–7.CrossRefPubMedPubMedCentral
16.
go back to reference Hida K, Maishi N, Torii C, Hida Y. Tumor angiogenesis--characteristics of tumor endothelial cells. Int Clin Oncol. 2016;21:206–12.CrossRef Hida K, Maishi N, Torii C, Hida Y. Tumor angiogenesis--characteristics of tumor endothelial cells. Int Clin Oncol. 2016;21:206–12.CrossRef
17.
18.
go back to reference Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464–78.CrossRefPubMed Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464–78.CrossRefPubMed
19.
20.
go back to reference Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The role of diffusion-weighted imaging (DWI) in locoregional therapy outcome prediction and response assessment for hepatocellular carcinoma (HCC): the new era of functional imaging biomarkers. Diagnostics. 2015;5:546–63.CrossRefPubMedPubMedCentral Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The role of diffusion-weighted imaging (DWI) in locoregional therapy outcome prediction and response assessment for hepatocellular carcinoma (HCC): the new era of functional imaging biomarkers. Diagnostics. 2015;5:546–63.CrossRefPubMedPubMedCentral
21.
go back to reference Nowosielski M, et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology. 2011;53:291–302.CrossRefPubMed Nowosielski M, et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology. 2011;53:291–302.CrossRefPubMed
22.
go back to reference Thoeny HC, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology. 2005;234:756–64.CrossRefPubMed Thoeny HC, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology. 2005;234:756–64.CrossRefPubMed
23.
go back to reference Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. 2001;56:607–20.CrossRefPubMed Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. 2001;56:607–20.CrossRefPubMed
24.
go back to reference Tofts PS, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–32.CrossRefPubMed Tofts PS, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–32.CrossRefPubMed
25.
go back to reference Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348–64.CrossRefPubMed Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348–64.CrossRefPubMed
26.
go back to reference Yanagisawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anti-Cancer Drugs. 2010;21:687–94.PubMed Yanagisawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anti-Cancer Drugs. 2010;21:687–94.PubMed
27.
go back to reference Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 2010;11:92–102.CrossRefPubMed Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 2010;11:92–102.CrossRefPubMed
28.
go back to reference Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7(1):91–101.CrossRefPubMed Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7(1):91–101.CrossRefPubMed
29.
go back to reference Meier R, et al. Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One. 2014;9:–e94972. Meier R, et al. Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One. 2014;9:–e94972.
30.
go back to reference Henriksson E, et al. 2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res. 2007;27:2155–9.PubMed Henriksson E, et al. 2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res. 2007;27:2155–9.PubMed
31.
go back to reference Al-Kadi OS, Watson D. Texture analysis of aggressive and nonaggressive lung tumor CE CT images. IEEE Trans Biomed Eng. 2008;55:1822–30.CrossRefPubMed Al-Kadi OS, Watson D. Texture analysis of aggressive and nonaggressive lung tumor CE CT images. IEEE Trans Biomed Eng. 2008;55:1822–30.CrossRefPubMed
32.
go back to reference Parikh J, et al. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology. 2014;272:100–12.CrossRefPubMed Parikh J, et al. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology. 2014;272:100–12.CrossRefPubMed
33.
go back to reference Ganeshan B, Abaleke S, Young RC, Chatwin CR, Miles KA. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging. 2010;10:137–43.CrossRefPubMedPubMedCentral Ganeshan B, Abaleke S, Young RC, Chatwin CR, Miles KA. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging. 2010;10:137–43.CrossRefPubMedPubMedCentral
34.
go back to reference Ng F, Kozarski R, Ganeshan B, Goh V. Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol. 2013;82:342–8.CrossRefPubMed Ng F, Kozarski R, Ganeshan B, Goh V. Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol. 2013;82:342–8.CrossRefPubMed
35.
go back to reference Chowdhury R, et al. The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol. 2014;87:20140065.CrossRefPubMedPubMedCentral Chowdhury R, et al. The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol. 2014;87:20140065.CrossRefPubMedPubMedCentral
Metadata
Title
A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis
Authors
Ming Meng
Huadan Xue
Jing Lei
Qin Wang
Jingjuan Liu
Yuan Li
Ting Sun
Haiyan Xu
Zhengyu Jin
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4684-z

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine